An undisclosed buyer entered into a a definitive agreement to acquire Axolotl Biologix, Inc. from Carmell Corporation (NasdaqCM:CTCX) on March 20, 2024. The consideration consists of 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.49 USD | +1.63% | -3.11% | -34.65% |
05-15 | Carmell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-11 | Carmell Corporation announced that it has received $3 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-34.65% | 65.99M | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- CTCX Stock
- News Carmell Corporation
- An undisclosed buyer entered into a a definitive agreement to acquire Axolotl Biologix, Inc. from Carmell Corporation ).